Ocular Therapeutix (OCUL) Other Accumulated Expenses (2013 - 2026)

Ocular Therapeutix has reported Other Accumulated Expenses for 14 years, with the latest figure at $2.6 million in Q2 2026.

• Other Accumulated Expenses for Q2 2026 came in at $2.6 million, up 53.5% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.6 million (up 53.5% YoY), and the FY2025 annual result was $1.9 million, down 6.76% from the prior year.
• Other Accumulated Expenses climbed to $2.6 million in Q2 2026, from $1.7 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.6 million in Q2 2026 and troughed at $1.1 million in Q2 2022.
• A 5-year average of $1.6 million and a median of $1.6 million in 2024 frame the typical range for Other Accumulated Expenses.
• The widest annual swing landed in 2024, when Other Accumulated Expenses soared 61.58%; it then declined 10.53% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $1.2 million in 2022, then climbed by 24.19% to $1.5 million in 2023, then surged by 34.75% to $2.1 million in 2024, then retreated by 6.76% to $1.9 million in 2025, then soared by 37.47% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $2.6 million in Q2 2026, $1.7 million in Q1 2026, and $1.9 million in Q4 2025.